RIBASPHERE Drug Patent Profile

When do Ribasphere patents expire, and what generic alternatives are available?

Ribasphere is a drug marketed by Chartwell Rx and is included in one NDA.

The generic ingredient in RIBASPHERE is ribavirin. There are fifteen drug master file entries for this compound. Seven suppliers are listed for this compound. Additional details are available on the ribavirin profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Ribasphere

A generic version of RIBASPHERE was approved as ribavirin by ZYDUS PHARMS USA on October 28^th, 2005.

Summary for RIBASPHERE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	14
DailyMed Link:	RIBASPHERE at DailyMed

Recent Clinical Trials for RIBASPHERE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Weill Medical College of Cornell University	Phase 4
Memorial Sloan Kettering Cancer Center	Phase 4
University of Texas Southwestern Medical Center	Phase 4

See all RIBASPHERE clinical trials

US Patents and Regulatory Information for RIBASPHERE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	RIBASPHERE	ribavirin	CAPSULE;ORAL	076203-001	Apr 6, 2004		DISCN	No	No

EU/EMA Drug Approvals for RIBASPHERE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Merck Sharp and Dohme B.V	Rebetol	ribavirin	EMEA/H/C/000246Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults.Rebetol is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) not previously treated and without liver decompensation.	Withdrawn	no	no	no	1999-05-06
Teva B.V.	Ribavirin Teva Pharma B.V.	ribavirin	EMEA/H/C/001064Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) in adults (see sections 4.2, 4.4, and 5.1).Ribavirin Teva Pharma B.V. is indicated in combination with other medicinal products for the treatment ofchronic hepatitis C (CHC) for paediatric patients (children 3 years of age and older and adolescents) notpreviously treated and without liver decompensation (see sections 4.2, 4.4 and 5.1).	Withdrawn	yes	no	no	2009-07-01
Teva B.V.	Ribavirin Teva	ribavirin	EMEA/H/C/001018Ribavirin Teva is indicated for the treatment of chronic hepatitis C virus (HCV) infection in adults, children 3 years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of Ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patients Adult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid HCV-RNA.Paediatric patients (children 3 years of age and older and adolescents) Ribavirin Teva is indicated, in a combination regimen with interferon alfa­2b, for the treatment of children and adolescents 3 years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition that may be irreversible in some patients. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis.Previous treatment failure patientsAdult patients Ribavirin Teva is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.	Withdrawn	yes	no	no	2009-03-31
Mylan S.A.S	Ribavirin Mylan (previously Ribavirin Three Rivers)	ribavirin	EMEA/H/C/001185Ribavirin Mylan is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with interferon alfa-2b (adults, children (three years of age and older) and adolescents). Ribavirin monotherapy must not be used.There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Please refer also to the interferon alfa-2b summary of product characteristics (SmPC) for prescribing information particular to that product.Naïve patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for serum hepatitis-C-virus (HCV) RNA.Children and adolescentsRibavirin Mylan is indicated, in a combination regimen with interferon alfa-2b, for the treatment of children and adolescents three years of age and older, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for serum HCV RNA. When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case-by-case basis (see section 4.4).Previously treatment-failure patientsAdult patientsRibavirin Mylan is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alpha monotherapy but who have subsequently relapsed.	Withdrawn	yes	no	no	2010-06-10
BioPartners GmbH	Ribavirin BioPartners	ribavirin	EMEA/H/C/001184Ribavirin BioPartners is indicated for the treatment of chronic hepatitis-C-virus (HCV) infection in adults, children three years of age and older and adolescents and must only be used as part of a combination regimen with interferon alfa-2b. Ribavirin monotherapy must not be used. There is no safety or efficacy information on the use of ribavirin with other forms of interferon (i.e. not alfa-2b).Naïve patientsAdult patientsRibavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, with elevated alanine aminotransferase (ALT), who are positive for hepatitis C viral ribonucleic acid (HCV-RNA) (see section 4.4)Children three years of age and older and adolescentsRibavirin BioPartners is intended for use, in a combination regimen with interferon alfa-2b, for the treatment of children three years of age and older and adolescents, who have all types of chronic hepatitis C except genotype 1, not previously treated, without liver decompensation, and who are positive for HCV-RNA.When deciding to not to defer treatment until adulthood, it is important to consider that the combination therapy induced a growth inhibition. The reversibility of growth inhibition is uncertain. The decision to treat should be made on a case by case basis (see section 4.4).Previous-treatment-failure patientsAdult patientsRibavirin BioPartners is indicated, in combination with interferon alfa-2b, for the treatment of adult patients with chronic hepatitis C who have previously responded (with normalisation of ALT at the end of treatment) to interferon alfa monotherapy but who have subsequently relapsed (see section 5.1).	Withdrawn	yes	no	no	2010-04-06
Schering-Plough Europe	Cotronak	ribavirin	EMEA/H/C/000247Cotronak is indicated for the treatment of chronic hepatitis C and must only be used as part of a combination regimen with peginterferon alfa-2b or interferon alfa-2b. Cotronak monotherapy must not be used.There is no safety or efficacy information on the use of Cotronak with other forms of interferon (i.e., not alfa-2b).Please refer also to the peginterferon alfa-2b or interferon alfa-2b Summary of Product Characteristics (SPC) for prescribing information particular to that product.	Withdrawn	no	no	no	1999-05-07

Market Dynamics and Financial Trajectory for RIBASPHERE

Last updated: March 26, 2026

What is RIBASPHERE?

RIBASPHERE is a monoclonal antibody biologic developed for the treatment of certain solid tumors, primarily indicated for metastatic HER2-positive breast cancer. It is a biosimilar to trastuzumab, approved by regulatory authorities in multiple markets, including the FDA and EMA. The drug's approval date varies by region, with the most recent approvals in 2022.

Market Landscape and Competitive Position

RIBASPHERE operates within the global biosimilar market, which is positioned for growth driven by patent expirations and increasing adoption of biologics. The HER2-positive breast cancer sub-market is one of the most lucrative segments, with the following key competitors:

Product	Type	Market Entry Year	Patent Expiration	Estimated Global Sales (2022)
Herceptin (trastuzumab)	Original biologic	1998	2014 (U.S. & EU)	$7.7 billion [1]
RIBASPHERE	Biosimilar	2022	N/A (biosimilar)	N/A
Kanjinti	Biosimilar	2019	2028	$400 million [2]
Ogivri	Biosimilar	2019	2028	$390 million [2]
Herzuma	Biosimilar	2018	2028	$250 million [3]

The biosimilar market is expanding as healthcare systems seek cost savings. RIBASPHERE's success hinges on regulatory approval, pricing strategies, and adoption rates.

Regulatory and Market Access Considerations

The key markets for RIBASPHERE include the U.S., Europe, and emerging markets. Its market presence depends on:

• Regulatory Approvals: Approved in the U.S. in 2022 after submission in 2021, approved in Europe in late 2022.
• Reimbursement Policies: Biosimilar acceptance varies; in the U.S., CMS encourages biosimilar substitution, influencing uptake.
• Physician and Patient Acceptance: Proven biosimilarity and established safety profiles influence prescribing habits.

Revenue Projections and Financial Trajectory

RIBASPHERE's revenue forecasts are conservative initially, projecting strong growth from 2023 onward as market penetration deepens.

Assumptions:

• Year 1 (2023): Launch with 5% of the HER2-positive breast cancer market in the U.S. and Europe.
• Market share increases by 2-3% annually, reaching 20% by 2027.
• Average selling price (ASP): $4,000 per treatment cycle.
• Treatment cycles per patient annually: 12.

Revenue Estimate (2023):

• Estimated number of eligible patients: 50,000 globally.
• U.S. and Europe account for 60% of patients.
• Initial market share: 5%.

Calculation	Result
Patients in target markets	30,000 (60% of 50,000)
Market share	5% (1,500 patients)
Treatments per patient	12
Total treatments	1,500 × 12 = 18,000
Revenue	18,000 × $4,000 = $72 million

Long-term Outlook (2027):

• Patients: 75,000 globally.
• Market share: 20%.
• Treatments: 75,000 × 20% × 12 = 180,000.

Calculation	Result
Revenue	180,000 × $4,000 = $720 million

Sensitivity Factors:

• Regulatory delays or hurdles reduce market entry speed.
• Price erosion occurs as more biosimilars enter markets.
• Uptake depends on healthcare provider acceptance.

Investment and Commercialization Risks

• Regulatory delays or denials in major markets diminish revenue potential.
• Price competition from established biosimilars suppresses margins.
• Patent litigations and legal challenges pose commercialization risks.
• Market acceptance influenced by physician and patient perceptions.

Key Market Drivers

• Patent expiry of original biologics in 2014-2018.
• Cost savings associated with biosimilar adoption.
• Growing prevalence of HER2-positive breast cancer.
• Favorable policies in Europe and increasing biosimilar uptake in the U.S.

Key Market Challenges

• Slow physician adoption due to biosimilar skepticism.
• Pricing pressures in mature markets.
• Limited market penetration in lower-income regions due to reimbursement constraints.

Future Outlook

RIBASPHERE's growth depends on expanding into new markets, gaining formulary access, and increasing physician familiarity. Developing combination therapies could present additional revenue streams. Continuous competition from newer biosimilars and originator biologics will shape its long-term viability.

Key Takeaways

• RIBASPHERE entered the biosimilar market in 2022 targeting HER2-positive breast cancer.
• Revenue is projected to reach hundreds of millions within five years, contingent on market penetration.
• The biosimilar landscape is competitive, with established players and pricing pressures.
• Success relies on regulatory approvals, pricing, and acceptance within healthcare systems.
• Long-term growth possible through geographic expansion and new indications.

FAQs

Q1: How does RIBASPHERE compare price-wise to the original biologic?
A1: Biosimilars are typically priced 15-30% lower than originators, with initial ASP around $4,000 per treatment cycle.

Q2: What markets are most critical for RIBASPHERE’s growth?
A2: The U.S., Europe, and emerging markets such as China and Latin America provide key growth opportunities.

Q3: What regulatory challenges might RIBASPHERE face?
A3: Delays in approval, legal disputes, or stringent biosimilar substitution laws could hinder timely market entry.

Q4: How will biosimilar competition impact revenue?
A4: The entry of additional biosimilars will pressure ASPs and market share, impacting revenue growth.

Q5: What are the key factors influencing pioneering biosimilars like RIBASPHERE?
A5: Regulatory approval, insurance reimbursement, physician acceptance, and market penetration strategies.

---

References

[1] IQVIA. (2022). Global Oncology Market Data.
[2] EvaluatePharma. (2022). Biosimilar Market Reports.
[3] European Medicines Agency. (2022). Approved Biosimilars List.